GLUE — Monte Rosa Therapeutics Inc

Monte Rosa Therapeutics Inc (GLUE) is a biotechnology company listed on NASDAQ. It is led by Markus Warmuth M.D., based in 321 Harrison Avenue, Boston, MA, United States, 02118, with about 187 employees. Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Net income was $7.5M. GLUE currently screens at market cap $1.56B.

Use this GLUE page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the GLUE quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the GLUE SEC filings page. Lician reads the product cache first so this HTML stays unique to Monte Rosa Therapeutics Inc even when a live quote feed is slow.